Luca joined the pharmaceutical industry as a Global Discovery Portfolio Manager in the Pharma Strategy Unit at Hoffmann-La Roche Ltd. He then pursued his career in the financial industry as a Fundamental Analyst at BT&T asset management, and as a freelance consultant. Subsequently, he was Director Business Development at Actelion before he joined Novimmune in the same function. In his last position as VP Corporate Licensing at Recordati Group Luca was member of the Executive Management responsible for licensing activities of Recordati with special emphasis on orphan diseases. He was also responsible for Recordati’s alliances. Currently, Luca serves on the three Boards, including the Swiss Biotech Association.
Luca studied biochemistry at the ETH in Zürich and completed his undergraduate studies with a Master in Immunology followed by a PhD in biochemistry from at the Biozentrum, University of Basel in biochemistry. He also was a member of the Basel Institute for Immunology.